You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Bioactive Prosthetic Vascular Graft

    SBC: BIOSURFACES INC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 60,000 prosthetic grafts, which are comprised of either polyethylene terephthalate (polyester) or expanded polytetrafluoroethylene (ePTFE), are implanted in the United States each year. Medium (6-8mm) and small (l t5mm) internal diameter (I.D.) prosthetic arterial grafts continue to have unacceptably high failure rates when used in the clinical setting. T ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. A BioPhysical Approach to Resuscitation Fluids

    SBC: BIOPHYZICA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Circulatory, hypoxemic or traumatic arrest claims an estimated 350,000 lives per year in the United States accounting for almost 15% of all deaths. Circulatory, hypoxemic, or traumatic arrests result in whole-body ischemia, most significantly global cerebral ischemia. Brain cells die when they no longer receive oxygen and nutrients from the blood. Because cereb ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. A Bullet Proof vascular graft to prevent dialysis access cannulation injury

    SBC: Innavasc Medical, Inc.            Topic: 400

    Project Summary Abstract Synthetic arteriovenous grafts AVGs can provide life sustaining vascular access for dialysis patients but are subject to multiple modes of failure and complications related to chronic needle cannulation poor graft identification delayed access and bleeding These graft needle cannulation associated complications translate to millions of dollars in health care expense ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Accessible and Robust High-Throughput Western Blotting for Small Sample Sizes

    SBC: BLOTTING INNOVATIONS, LLC            Topic: 400

    PROJECT SUMMARY The goal of this Phase I STTR is for Blotting Innovations, LLC to establish feasibility of a commercializable mesowestern—a high-throughput, affordable western blotting technique that we recently developed. Western blotting is a technique for molecular-weight-resolved analysis of proteins and their post-translational modifications that is practiced today almost identically to whe ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. A cell-free, high-throughput screening service for accelerated GPCR ligand discovery

    SBC: KXT BIO INC.            Topic: 300

    PROJECT SUMMARY The proposed Phase I STTR project is a partnership between a biotechnology company KXTbioIncand the University of North Carolina at Chapel Hill to develop an innovative high throughput screening service for identifying new drug candidates that act via G protein coupled receptorsGPCRsThis large protein superfamily has been the most successful source of therapeutic targetsaccounting ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Acid Ceramidase, Target for Cancer

    SBC: Sphingogene, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Acid ceramidase (AC) has been implicated as a novel target for cancer therapy because of its pivotal role in regulating interconversion of three key bioactive lipids; ceramide (Cer), sphingosine (Sph) and Sphingosine-1-Phosphate (S1P). It is well known that Cer functions predominantly as a tumor suppressor lipid and mediator of apoptosis following chemo and rad ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. A cloud-based digital health navigation program for colorectal cancer screening

    SBC: DIGITAL HEALTH NAVIGATION SOLUTIONS, INC.            Topic: 102

    Over 30% of age-eligible Americans fail to receive recommended screening for colorectal cancer (CRC), the second leading cause of cancer death in the United States. Multilevel barriers explain why so many Americans fail to receive routine CRC screening. Patients report a lack of knowledge about the need for screening or their screening options, and many view screening as messy, uncomfortable, or e ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. ACOUSTIC PROCESSING OF SPEECH TO IMPROVE ELECTROLARYNX COMMUNICATION

    SBC: SENSIMETRICS CORP            Topic: N/A

    DESCRIPTION (provided by applicant): Over half of laryngectomy patients use an electrolarynx (EL) to communicate, but current EL devices produce speech that has poor quality ("non-human sounding") and reduced intelligibility. The acoustic deficits in EL speech inhibit the ability of laryngectomy patients to communicate, thus reducing their functional capability and quality of life. The long-term g ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Addressing bone marrow lesions that compromise osteochondral tissue repair

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Degenerative joint diseases such as osteoarthritis (OA) remain the source of significant pain and disability, affecting over 30 million adults with an annual US economic burden of more than $486 billion. Joint replacement is a well-established procedure, but its finite life span makes this treatment unacceptable for younger (under 65) or more active individuals. For this growing patient p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government